Frontiers in Pediatrics | www.frontiersin.org
1 April 2019 | Volume 7 | Article 159
Eine wachsende Anzahl von Studierenden interessiert sich für Global Health. Bisher mangelt es jedoch an ausreichenden Angeboten zur Verwirklichung von studentischen Global-Health-Forschungsprojekten. Um vor diesem Hintergrund interessierte Studierende auf ihrem Weg zum eigenen Global-Health-Forschu...ngsprojekt zu unterstützen, hat die AG Forschungsplattform der Global Health Alliance-Deutschland (GHA-D), in Kooperation mit weiteren Institutionen, das Handbuch "Forschung mit Weitblick" entwickelt. Neben Hintergrundinformationen und Anregungen zur kritischen Reflexion werden in dem Handbuch eine Auswahl von Forschungsarbeiten mit Global-Health-Bezug sowie erste Schritte zur Umsetzung eines eigenen Forschungsprojekts vorgestellt.
more
This document focuses on making recommendations for the diagnosis and treatment of Chagas disease, an infection caused by Trypanosoma cruzi, the protozoan agent of a systemic parasitic disease. Methodology: These clinical practice guidelines were prepared following the WHO handbook for guideline dev...elopment (5). A multidisciplinary development group was formed, comprised of thematic experts, epidemiologists, methodologists, and users. Since there were no existing guidelines that could be adapted, the guidelines were developed from scratch.
more
Esta guía está enfocada en emitir recomendaciones para el diagnóstico y el tratamiento de la enfermedad de Chagas, como infección por Trypanosoma cruzi, agente protozoario de una parasitosis sistémica. Metodología: La presente guía de práctica clínica fue confeccionada siguiendo los método...s de elaboración de guías de la OMS (5). De forma general, se conformó un grupo desarrollador multidisciplinario compuesto por expertos temáticos, epidemiólogos, metodólogos y usuarios. Dado que no se identificaron guías susceptibles de ser adaptadas, la guía se desarrolló de novo.
Updated guideline, June 2019
more
Diese Broschüre möchte dazu beitragen, dass möglichst viele Menschen die Ergebnisse öffentlich finanzierter Forschung nutzen können.
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant ...and breastfeeding women, children and adolescents. The Global Action Plan has five strategic objectives: 1) prevention and response; 2) monitoring and surveillance; 3) research and innovation; 4) laboratory capacity; and 5) governance and enabling mechanisms.
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
BUKO Pharma-Kampagne has investigated the causes and consequences of antibiotic resistance in India, South Africa, Tanzania and Germany. Together with our partners we collected data and did interviews with numerous stakeholders. The outcome is presented in a brochure that is now available in English...
Resistant bacteria are spreading worldwide. In collaboration with partners in India, Tanzania, South Africa and Germany, we have investigated the causes and consequences of this spread.2 This Pharma-Brief Special presents the results. It examines the risks for humans, animals and the environment. It focuses on local problems and approaches, international interactions and the re-sponsibility of doctors, farmers and consumers.
more
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...rmaceutical products, including product pricing, the regulatory environment and patent status, which together shape the national hepatitis response in different settings. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
more
On 9 February 2021, a first webinar entitled “Expanding our understanding of Post COVID-19 condition” was held under the auspices of WHO and in consultation with the International Severe Acute Respiratory and Emerging Infection Consortium(ISARIC), Global Research Collaboration for Infectious Dis...ease Preparedness (GloPID-R), National Institutes of Health/National Institute of Allergy and Infectious Diseases(NIH/NIAID), Long Covid SOS and patient representatives.
more
July 2021. This publication brings together important clinical and programmatic updates produced by WHO since 2016 and provides comprehensive, evidence-informed recommendations and good practice statements within a public health, rights-based and person-centred approach.
These guidelines bring in... the most recent guidance on HIV testing strategies - the entry point for HIV prevention and treatment - and include comprehensive guidance on infant diagnosis. Key recommendations are presented on rapid antiretroviral therapy (ART) initiation and the use of dolutegravir. Updated recommendations are included on the timing of ART for people with TB, and the use of point-of-care technologies for treatment monitoring.
more
English Analysis on World and 26 other countries about Agriculture, Climate Change and Environment, Drought, Epidemic and more; published on 26 Oct 2021 by WMO
Glob Heart . 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.
Em meados de 2021, os programas nacionais de SIDA começaram a fazer a transição do tratamento para crianças que vivem com VIH dolutegravir (DTG) 10 mg sulcado, comprimidos dispersíveis, também conhecido como DTG pediátrico (pDTG). A rápida introdução e implementação do pDTG é uma priori...dade para implementar as diretrizes da Organização Mundial da Saúde (OMS) e garantir que as crianças que vivem com VIH recebam o melhor tratamento disponível da SIDA de primeira e segunda linha o mais rápido possível. É importante notar que uma única substituição pDTG deve ocorrer independentemente da disponibilidade de um teste/carga viral (CV), ou do valor do último resultado de CV, mantendo ou otimizando as crianças usando abacavir/lamivudina (ABC/3TC) como base. Atualmente, mais de 30 países têm planos de adoção e implementação do pDTG.
more
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...two to four; and the recommendation for intralesional antimonials is now strong. For mucosal leishmaniasis there is now a strong recommendation for use of pentavalent antimonials with or without oral pentoxifylline. For visceral leishmaniasis, the strong recommendations for use of pentavalent antimonials and amphotericin B deoxycholate are now conditional.
more
The sixteenth meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases (STAG-NTD) was held as a hybrid meeting, 27–28 September 2022.
Dr Ren Minghui, Assistant Director-General, Universal Health Coverage/Communicable and Noncommunicable Diseases, welcomed participan...ts to the meeting. He said the World Health Organization’s Department of Control of Neglected Tropical Diseases (WHO/NTD) was in a state of transition. Following the death of the late esteemed Director Dr Mwelecele Ntuli Malecela earlier in the year, Dr Gautam Biswas had taken over as Acting Director but would soon retire; the appointment of a new Director was under way. Owing to rotation of STAG-NTD members, this would be the last meeting for some and the first meeting for several new participants. The work however would continue with the same commitment. Discussions over the next two days would focus on critical issues regarding recovery of NTD services following the disruptions caused by coronavirus disease (COVID-19), which had impacted many health services worldwide. He looked forward to receiving the advice and guidance of STAG-N
more
Not long ago, on the occasion of the 100th anniversary of the discovery of Chagas disease, several campaigns denounced the scant progress has been made in diffrent spheres- medical, scientific and politcal- but major challanges still remain. This is an appropriate time to celebrate what has been ach...ieved and to take the next step.
more